Microsoft word - press release english v3.doc

China Grand Pharmaceutical and Healthcare Holdings Limited (Incorporated in Bermuda with limited liability) China Grand Pharmaceutical expands her new product pipeline with an eye on the future Wuhan Grand Pharmaceutical Group Company Limited, a subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited, signed agreements on the product development and technology transfer of four projects with Tianjin Institute of Pharmaceutical Research and Xi’an Xintong Drug Research Company Limited, respectively. The four projects are: Olprinone injection (a Category 3.1 new drug), Candesartan cilexetil and Hydrochlorothiazide capsules (a Category 3.2 new drug), Penciclovir injection (a Category 2 new drug) and Amlodipine Besylate and Telmisartan tablets (a Category 3.2 new drug). Under the terms of the Agreement, these new products are scheduled to be on the market in 2012 and thereafter. Wuhan Grand Pharmaceutical Group Company Limited will possess the rights to manufacture and market the above four products in the mainland China. Under the terms of the agreement, Tianjin Institute of Pharmaceutical Research will be responsible for clinical research, regular filing, registration, declaration and certification of Candesartan cilexetil and Hydrochlorothiazide capsules as a state new drug. The capsule is a compound preparation for hypertension, popular in European and American markets and is now under clinical research as a state Category 3 new drug in the mainland China. Under the terms of the agreement, Xi’an Xintong Drug Research Company Limited will be responsible for clinical research, regular filing, registration, declaration and certification of Olprinone injection and Penciclovir injection as a state new drug, respectively and for pre-clinical research, regular filing, declaration and approvals of Amlodipine Besylate and Telmisartan tablets for clinical study in China. Olprinone injection is a Category 3 new drug, which is a new generation of phosphodiesterase III inhibitor for the treatment of heart failure. This product is more effective and safer than similar drugs in the market such as Milrinone and Inamrinone. Penciclovir is a medicine for severe herpes virus infection, but is only for external use in European and American markets because of its poor absorption if taken orally. Penciclovir injection (transfusion) is registered and declared as a Category 2 new drug by changing the route of administration. It will provide a new medication for severe herpes zoster virus infection. The product has passed Phase-II clinical trials and it will enter Phase III. Amlodipine Besylate and Telmisartan tablet is now the most unique and latest compound preparation for hypertension in which the pre- clinical research has been completed, it will be registered and declared as a Category 3 new drug in China. Wuhan Grand Pharmaceutical Group Company Limited has been building a full and sustainable new product pipeline through the internal research and development, and the external project cooperation and product licensing. The development of Candesartan cilexetil and Hydrochlorothiazide capsules, Olprinone injection and Telmisartan/ Amlodipine tablet will effectively expand her new product pipeline in cardiovascular therapeutic area; the development of Penciclovir injection will further reinforce the Company’s market position in anti-infective therapeutic area. Wuhan Grand Pharmaceutical Group Company Limited is a well-known mainland China-based pharmaceutical enterprise. Tianjin Institute of Pharmaceutical Research is a national integrated pharmaceutical research institute administrated directly under the State Food and Drug Administration. As a high-tech enterprise mainly engaged in new drug research, it is one of the most powerful and influential research institutes. Xi’an Xintong Drug Research Company Limited is a high-tech pharmaceutical research enterprise in Shaanxi Province with a strong research team, advanced facilities and high productivity. It is mainly engaged in research and development of chemical medicines and traditional Chinese medicines including pre-clinical studies, clinical studies, regular filing, product registration as well as technology transfer and consultation.

Source: http://www.hklistedco.com/pdf/CONS/CHNGRAND/100728_E0512.pdf